ASCE+ HRLV for Hair Thinning: How the Regenerative Formula Works

ASCE+ HRLV for Hair Thinning: How the Regenerative Formula Works

Medically reviewed by Dr. Hyunju Kim, Medical Director, Mason Clinic

Hair thinning is one of the most common concerns patients bring to an aesthetic clinic, and the range of treatments now marketed for it can be difficult to sort through. ASCE+ HRLV is one such option offered at Mason Clinic in Seoul: an injection-based hair-loss treatment that uses what its manufacturer describes as a next-generation regenerative ASCE+ formula, delivered directly into the scalp to support the scalp environment and the natural hair growth cycle. This article explains what the treatment involves, how the clinic approaches it, who it may suit, and—importantly for readers in the United States—what its regulatory status actually is. Because ASCE+ is marketed as an exosome-based product, its regulatory picture in the US is specific and important, and we cover it plainly below. This guide is educational and is not a self-diagnosis tool; only an in-person medical evaluation can determine whether any hair-loss treatment is appropriate for you.

What ASCE+ HRLV Is

ASCE+ HRLV is described by Mason Clinic as a specialized, injection-based hair-loss treatment intended to support scalp health and strengthen hair follicles using a next-generation regenerative ASCE+ formula. Rather than a surgical procedure, it is delivered through injections placed directly into the scalp. The stated aim is to improve the scalp environment and support the natural hair growth cycle through a medically guided treatment process.

The word "regenerative" appears frequently in the marketing of ASCE+ products, so it is worth being precise about what that term does and does not mean here. ASCE+ is a product family made by ExoCoBio and is marketed as an exosome-based regenerative product. Exosomes are tiny vesicles that cells release, and products built around them are promoted for a variety of signaling and tissue-support purposes. In the context of ASCE+ HRLV, the formula is positioned as a way to support the follicles and the scalp environment rather than as a mechanical restoration of hair.

At Mason Clinic, ASCE+ HRLV sits within a broader Hair & Scalp Therapy category that also includes M Cell Hair Conditioning, the Alopecia Areata Injection, and Hair Follicle Botox Injection. Each of these takes a different approach, and choosing among them is something the clinic frames as a decision to be made with a physician after an individual scalp evaluation.

Regulatory Status: What US Patients Need to Know

This is the single most important section for readers based in the United States, and it deserves to be read carefully before anything else.

No exosome product is approved by the US Food and Drug Administration (FDA) for any use. That is a categorical statement, not a nuance. The FDA has issued a Public Safety Notification on exosome products, and it has issued warning letters to companies marketing them. The agency has also published a consumer alert about regenerative medicine products, including stem cells and exosomes, cautioning the public that many such products are being marketed without FDA approval and without adequate evidence of safety or effectiveness for the uses being advertised.

ASCE+ is FDA-listed, but being listed is not the same as being approved. Listing refers to a manufacturer registering a product with the FDA; it does not mean the FDA has reviewed the product and found it safe and effective for a particular use. ASCE+ HRLV is not FDA-approved in the United States, and regenerative and exosome-based products in this category are, as a group, unapproved in the US.

What this means in practice: ASCE+ HRLV is offered at Mason Clinic in Seoul under the local regulatory framework that applies there. It should not be assumed to carry US FDA approval, and its availability in Seoul does not imply that a US regulator has cleared it. Results vary from person to person and cannot be guaranteed. Anyone considering the treatment should discuss the potential benefits, the limits of the current evidence, and the possible risks directly with the treating physician before proceeding. This article does not promise regrowth, and neither the clinic's materials nor this guide should be read as making such a promise.

How the Treatment Works, Step by Step

Mason Clinic describes the ASCE+ HRLV process as a structured, doctor-led sequence rather than a single quick injection.

First, the scalp is evaluated and prepared before treatment. This is not a formality—it is the step that shapes the entire plan. The clinic states that a doctor evaluates your scalp condition, hair-loss pattern, follicle health, and treatment suitability before creating a personalized ASCE+ HRLV treatment plan. The consultation may include a precision ultrasound assessment of the scalp and tissues, followed by a doctor-led discussion to determine the most appropriate approach.

Once the plan is set and the scalp is prepared, the ASCE+ HRLV formula is injected directly into the scalp. The procedure is incision-free, which is part of why it is described as non-surgical. According to the clinic, most patients can resume daily activities shortly afterward, and follow-up visits are used to monitor scalp health and treatment progress over time.

On the technical side, the clinic notes several details about how delivery is handled. The injection-based approach is intended to target the treatment directly to the hair follicles and scalp. Precision ultrasound-guided assessment supports personalized treatment planning. And to help with comfort during the session, the clinic uses PRESS technology and microneedle-assisted delivery. These comfort measures are part of Mason Clinic's broader, individualized pain-minimization approach, which across its services may include advanced PRESS devices, anesthetic cream absorption, microneedling, pain-relief injections, or nerve anesthesia when appropriate. The specific comfort measures used for any given patient are decided in consultation.

The Diagnostic-First Scalp Assessment

One of the features Mason Clinic emphasizes is that treatment is diagnostic-first. Before an ASCE+ HRLV plan is finalized, the scalp is assessed rather than treated on a fixed template. The clinic's precision ultrasound assessment is used to look at the scalp and underlying tissues, and this information feeds into the doctor-led discussion about whether the treatment is suitable and how it should be planned.

This matters for two reasons. First, hair thinning has many possible causes, and an assessment helps a physician consider what is actually driving an individual's concern. Second, it reinforces a point this article returns to repeatedly: candidacy is an individual medical judgment, not something that can be decided from an online description. The clinic offers a director-led one-on-one consultation on request, and an online consultation is also possible for patients planning travel from abroad.

Mason Clinic also describes broader practices intended to support a safe and transparent experience: private treatment rooms, professional care throughout the process, genuine products with the correct dosage opened in front of the patient with photo documentation, and structured aftercare. These are general clinic practices rather than efficacy claims about ASCE+ HRLV specifically.

Who May Be a Candidate

Based on the clinic's materials, ASCE+ HRLV may be considered for people who:

• Have progressive hair loss or ongoing hair thinning.
• Have weakened or damaged hair follicles that may benefit from scalp support.
• Experience reduced hair density or weaker hair strands.
• Have scalp imbalance, such as excess sebum or other conditions affecting scalp health.
• Want a non-surgical, injection-based option to support scalp health and the natural hair growth cycle after a medical evaluation, with minimal downtime.

Just as important is who should not proceed without a careful conversation. The clinic lists suitability screening as part of the doctor's evaluation, and contraindications for this specific treatment are something the clinic confirms individually rather than publishing as a fixed list. If you have a medical condition, take medications, are pregnant or breastfeeding, or have any doubt about whether the treatment is right for you, that is a discussion to have with the physician. The presence of a bullet point above that seems to describe your situation is not a substitute for a professional assessment.

Realistic Expectations, Results, and Risks

It is worth stating clearly what ASCE+ HRLV is positioned to do and what it is not. The treatment is described as supporting the scalp environment and the natural hair growth cycle. It is not presented here as a guaranteed cure for hair loss, and results vary from person to person. No specific outcome, timeline, or degree of change can be promised.

Because the clinic's published materials list several details for this treatment as "Needs Clinic Confirmation"—including specific risks, side effects, recovery timeline, and how long any results might last—those are precisely the points to raise directly with the treating physician. As a general matter, injection-based scalp treatments can carry risks such as injection-site redness, swelling, bruising, or tenderness. The clinic states that it reduces risk through an individualized scalp evaluation before treatment, structured doctor-led injection protocols, patient-specific pain-management methods, and transparent treatment practices. None of these measures removes risk entirely, and a personalized discussion of your specific situation is the appropriate way to understand it.

For US readers, the regulatory context above is part of the risk picture too: because exosome-based products are unapproved in the US, the body of independent, regulator-reviewed evidence you might expect for an FDA-approved product is not present here. That is a reason to ask thorough questions, not to make assumptions.

How ASCE+ HRLV Differs From Mason Clinic's Other Scalp Treatments

Patients researching hair thinning at Mason Clinic will encounter several services, and it helps to understand that they are not interchangeable.

ASCE+ HRLV uses the injected ASCE+ regenerative formula to support the follicles and scalp environment. M Cell Hair Conditioning, by contrast, is a regenerative scalp treatment that uses an autologous, tissue-based M CELL solution delivered through micro-injections—meaning it is built around the patient's own biological material rather than a manufactured exosome-marketed formula. Hair Follicle Botox Injection takes yet another route, focusing on the scalp muscle layer to reduce scalp tension and support the hair-root environment. The Alopecia Areata Injection is a customized approach for immune-related, inflammatory hair loss, a distinct clinical situation.

The practical takeaway is that these treatments target different aspects of scalp and hair health, and which one—if any—is appropriate depends on an individual evaluation. It is common for the right answer to become clear only after a physician has assessed the scalp.

FDA-Approved Hair-Loss Options Exist in the US

For general context, and without suggesting that ASCE+ HRLV is equivalent to them, it is worth knowing that there are hair-loss treatments approved by the FDA in the United States. According to Mayo Clinic, medications such as minoxidil and finasteride are used for pattern hair loss, and other approaches exist depending on the cause and pattern of loss. These are mentioned here only so that US readers understand the broader landscape; they are different products with different evidence, and ASCE+ HRLV should not be assumed to work the same way or to deliver the same results. A physician can help you weigh regulated options against treatments offered abroad.

Bottom Line

ASCE+ HRLV is a non-surgical, injection-based hair-thinning treatment offered at Mason Clinic in Seoul, built around an exosome-marketed regenerative ASCE+ formula and anchored by a diagnostic-first scalp assessment. For US patients, the essential fact is regulatory: no exosome product is FDA-approved for any use, the FDA has issued a Public Safety Notification on exosome products, and ASCE+ is FDA-listed but not FDA-approved. The treatment is offered under local regulation in Seoul, results vary and cannot be guaranteed, and there is no promise of regrowth. If you are considering it, the right next step is a thorough, individualized conversation with a physician about the evidence, the limits, and the risks. This article is educational and is not a self-diagnosis tool.

Frequently Asked Questions

**Who is generally considered a candidate for ASCE+ HRLV?**The clinic describes possible candidates as people with progressive hair loss or ongoing thinning, weakened or damaged follicles, reduced hair density, or scalp imbalance such as excess sebum, who want a non-surgical, injection-based option after a medical evaluation. Suitability is confirmed individually by a doctor, not from an online description.

**Is ASCE+ HRLV FDA-approved?**No. ASCE+ is marketed as an exosome-based product, and no exosome product is FDA-approved for any use in the United States. ASCE+ is FDA-listed, but listing is not approval. The treatment is offered in Seoul under local regulation. Discuss this status with the physician before proceeding.

**Will it make my hair grow back?**No regrowth is promised. The treatment is described as supporting the scalp environment and the natural hair growth cycle, but results vary from person to person and cannot be guaranteed. A physician can give you a realistic, individualized picture.

**How is the treatment delivered?**After a scalp evaluation that may include a precision ultrasound assessment, the ASCE+ HRLV formula is injected directly into the scalp. The procedure is incision-free, and the clinic uses PRESS technology and microneedle-assisted delivery to support comfort. Most patients can resume daily activities shortly afterward.

**How is ASCE+ HRLV different from M Cell Hair Conditioning?**ASCE+ HRLV uses an injected ASCE+ regenerative formula marketed as exosome-based, while M Cell Hair Conditioning uses an autologous, tissue-based solution derived from the patient's own material. They work differently, and a physician can advise which, if either, suits your situation.

**Can I have an online consultation before traveling?**Yes. The clinic states that an online consultation is possible and that an English-speaking team is available, which can help patients planning travel from abroad prepare for an in-person evaluation.

Disclaimer

This article is for general educational purposes only and is not medical advice, a diagnosis, or a self-diagnosis tool. It does not establish a doctor–patient relationship. Candidacy for any hair-loss treatment requires an in-person consultation and scalp assessment. Regulatory status differs by country: ASCE+ HRLV is offered in Seoul under local regulation and is not FDA-approved in the United States; no exosome product is FDA-approved for any use in the US. Results vary and cannot be guaranteed, and no regrowth is promised. Discuss the potential benefits and risks with a qualified physician before making any decision.